We are glad to announce an interesting paper from Prof Claudia Biguetti, about a study in which has been used 3S-HMGB1, LPS-Free (HM-130) produced by HMGBiotech.
Diabetes is well known to compromise bone regeneration and increase the risk of early implant failure due to impaired osteogenic responses. In this study, the authors investigated whether a single local administration of redox-stable 3S-HMGB1 could improve early osseointegration in a mouse model of type 2 diabetes.
Key findings from the study include:
- Diabetic mice showed impaired bone healing and reduced osteogenic activity compared with non-diabetic controls.
- 3S-HMGB1 treatment significantly improved peri-implant bone regeneration, increasing bone volume and restoring bone-to-implant contact close to non-diabetic levels, while also enhancing collagen organization.
These conclusions indicate that a single injection of redox-stable 3S-HMGB1 may represent a promising regenerative strategy to improve early implant integration and mitigate implant failure associated with diabetes. Future research concerning HMGB1 protein may explore sustained delivery approaches to further enhance long-term outcomes.
At HMGBiotech Srl, we provide comprehensive information to facilitate informed decision-making for researches with HMGB1.
Discover our 3S-HMGB1 Protein
Read the full article about the study
